BridgeBio Pharma Enters New Material Agreement and Terminates Prior One

BridgeBio Pharma Inc. (BBIO) disclosed entry into a material definitive agreement along with termination of another material definitive agreement in an 8-K filed with the SEC on May 8, 2026.

The filing covers Item 1.01 for the new agreement, Item 1.02 for the termination, and Item 9.01 for related financial statements and exhibits. Per the SEC EDGAR record, the company with CIK 0001743881 and ticker BBIO submitted the form under accession number 0001140361-26-019761.

The new agreement and the terminated agreement each carry operational scope for BridgeBio, which maintains a portfolio of drug development programs. The bundle does not disclose the counterparty names, contract types such as financing or partnership, or any dollar amounts attached to either agreement.

Operationally the company shifts from the prior contractual state under the terminated agreement to the new set of obligations under the replacement agreement. The filing itself takes effect immediately upon submission to the SEC on May 8, 2026. No future effective date for the contracts is stated in the record.

Downstream the company must incorporate the exhibits referenced in Item 9.01 into its public record, allowing investors and regulators to examine the precise terms. The termination ends any remaining performance obligations or rights under the prior contract.

Standard SEC rules now require BridgeBio to reflect the accounting impact of both the entry and the termination in its next quarterly or annual report. If either agreement involves clinical or regulatory milestones, those timelines reset according to the new contract language.

This filing follows BridgeBio's pattern of periodic 8-K disclosures to report material contract changes. The SEC requires public companies to file an 8-K within four business days of entering or terminating agreements that a reasonable investor would consider important.